KR20170049693A - Pharmaceutical composition for preventing or treating hypertriglyceridemia comprising methyl linolenate - Google Patents

Abstract

The present invention relates to: a pharmaceutical composition comprising methyl linolenate for preventing or treating hyperlipidemia including hypertriglyceridemia; a method for preventing or treating hyperlipidemia comprising a step of administering the pharmaceutical composition; a food composition for preventing or ameliorating hyperlipidemia comprising the methyl linolenate; a feed composition for preventing or ameliorating hyperlipidemia comprising the methyl linolenate; and a pharmaceutical composition for preventing or treating hyperlipidemia comprising excessive fractions. The composition comprising the methyl linolenate provided in the present invention is free of side effects, and can effectively prevent, treat or ameliorate hyperlipidemia, thereby being widely used for development of hyperlipidemia drugs in various forms.

Description

[0001] The present invention relates to a pharmaceutical composition for preventing or treating hypertriglyceridemia,

The present invention relates to a pharmaceutical composition for the prevention or treatment of hypertriglyceridemia comprising methylninolenic acid salt, and more particularly to a pharmaceutical composition for prevention or treatment of hyperlipidemia including hyperlipidemia including methylninolenic acid salt A pharmaceutical composition, a method of preventing or treating hyperlipidemia comprising the step of administering the pharmaceutical composition, a food composition for preventing or improving hyperlipidemia including the methyl linolenic acid salt, a feed composition for preventing or improving hyperlipidemia including the methyl linolenic acid salt And fractions thereof. The present invention also relates to a pharmaceutical composition for preventing or treating hyperlipemia.

In modern society, the obesity population is rapidly increasing due to the convenient living environment due to rapid automation, the excessive nutrition consumption due to the increase of processed food and eating out, and the decrease of the physical activity, and accordingly, the insulin resistance, dyslipidemia, hypertension, Metabolic diseases such as arteriosclerosis and hyperlipidemia are increasing.

Hyperlipidemia refers to a state in which abnormal amounts of lipids such as free cholesterol, cholesterol ester, phospholipid, and triglyceride are increased in the blood. Hyperlipidemia is not usually symptomatic in itself, but if there is a lot of fat in the blood, it sticks to the wall of the blood vessel and causes atherosclerosis, which can cause coronary heart disease, cerebrovascular disease, peripheral vascular occlusion (E. Falk et al., Circulation 92, 657-671, 1995). In addition, the excessive fat component as described above accumulates in the liver tissue, which may cause fatty liver. In the above, the proportion of fat in the liver exceeds 5% by weight of the liver, and can be induced not only by excessive fat intake but also by alcohol consumption.

On the other hand, as a method for decreasing the blood lipid concentration, it is recommended that diet, exercise, and medication to suppress the intake of foods containing a lot of cholesterol or saturated fatty acid and to reduce caloric intake. However, diet and exercise therapy are difficult to manage and implement strictly, and there are many limitations in its effectiveness. The lipid concentration reduction agents developed so far include bile acid binding agents, agents that lower cholesterol levels such as HMG-CoA Reductase Inhibitors, Neomycin, and Probucol, and fibrin acid derivatives, Drugs that lower the triglyceride content such as nicotinic acid and fish oil have been developed and used as therapeutic agents. However, these drugs have side effects such as hepatotoxicity, gastrointestinal disorders and carcinogenicity.

Accordingly, studies on natural products that can prevent or treat hyperlipidemia, arteriosclerosis and fatty liver by reducing the excess lipid concentration in the blood even though they are safe to the human body and have no side effects are underway. For example, methanol extracts from cultured wild ginseng have been reported to lower total cholesterol and LDL-cholesterol levels and elevate HDL-cholesterol levels in hyperlipidemic rats induced by high fat diet (EJ Lee et al. , Kor J. Pharmaceon, 34: 179-184, 2003). In addition, it has been reported that petroleum ether extract of Panax ginseng and Panaxydol, an ingredient of the extract, have an activity of inhibiting cholesterol absorption (HCHyun et al., J. Ginseng Res., 25: 162 (2001), Cholesterol lowering effects of altitude, gonorrhea and oyster mushroom powder have been reported (BK Kim et al., J. Korean Soc. Food Sci., Nutr., 30, 510-515, 2001).

Under these circumstances, the inventors of the present invention have made extensive efforts to develop a pharmaceutical agent capable of preventing or treating a disease caused by hyperlipidemia such as hypertriglyceridemia. As a result, it has been found that methyl linoleate inhibits the differentiation of adipocytes, And the present invention has been completed.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating hyperlipemia comprising methyl linolenic acid salt.

Another object of the present invention is to provide a method for preventing or treating hyperlipidemia comprising the step of administering the above pharmaceutical composition.

It is still another object of the present invention to provide a food composition for preventing or improving hyperlipidemia comprising the methyl linolenic acid salt.

Another object of the present invention is to provide a feed composition for preventing or improving hyperlipidemia comprising the methyl linolenic acid salt.

It is a further object of the present invention to provide a pharmaceutical composition for the prevention or treatment of hyperlipidemia comprising an excess fraction.

The present inventors have developed a pharmaceutical agent capable of preventing or treating a disease caused by hyperlipidemia such as hypertriglyceridemia, and found out that the over-extract is effective for the prevention or treatment of hyperlipidemia and applied for a patent Open Patent No. 2014-0113198). As a result, various studies have been carried out to find out effective ingredients showing the effect of preventing or treating hyperlipidemia contained in the over-extract. As a result, it has been confirmed that the effective ingredient showing the preventive or therapeutic effect of hyperlipemia contained in the over-extract is methylninolenic acid Respectively. That is, it was confirmed that the methylninolate was separated and purified from the overexpressed extract and treated at the time of differentiation of lipid precursor cells, and as a result, it was confirmed that the differentiation into adipocytes was inhibited in a concentration-dependent manner. An effective ingredient showing the effect of preventing or treating hyperlipidemia contained in such an over-extract has not been known so far and was firstly described by the present inventor.

In order to achieve the above object, the present invention provides, as one embodiment, a pharmaceutical composition for preventing or treating hyperlipidemia comprising methyl linolenic acid salt.

The term " methyl linolenate " in the present invention is a methyl salt of linolenic acid, which is an unsaturated fatty acid having three double bonds and a carboxylic acid, and is represented by the molecular formula of C ₁₉ H ₃₂ O ₂ and has a molecular weight of 292.46 And the compound represented by the following formula (1).

In the present invention, the methyl linolenic acid salt may be used as an active ingredient of a pharmaceutical composition for the prevention or treatment of hyperlipemia.

The term " hyperlipidemia "of the present invention means a state in which a large amount of lipid component is present in the blood and accumulates in blood vessels and causes inflammation, resulting in cardiovascular diseases, and the hyperlipidemia is hyperlipidemia (hyperlipidemia) Hypertriglyceridemia, hypercholesterolemia, artery hardening, and the like.

The term "prevention" of the present invention means any action which inhibits or delays disease by administration of a composition comprising the over-extract.

The term "treatment" of the present invention means all the actions of improving or alleviating symptoms of hyperlipidemia by administration of a composition containing the over-extract.

According to one embodiment of the present invention, methylene linoleate was obtained from the excess extract through various stages of separation and purification (FIG. 1), and the obtained methyllinolenic acid salt was treated in the differentiation process of lipid precursor cells. As a result, (Fig. 2 (a) and (b)).

The composition of the present invention may be prepared in the form of a pharmaceutical composition for the prevention or treatment of hyperlipidemia, which further comprises an appropriate carrier, excipient or diluent conventionally used in the production of a pharmaceutical composition, non-naturally occuring carrier. Specifically, the pharmaceutical composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method . In the present invention, the carrier, excipient and diluent which may be contained in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate , Calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it can be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, sucrose, lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use may include various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc. in addition to water and liquid paraffin, which are simple diluents commonly used in suspension, liquid solutions, emulsions and syrups have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like can be used.

The content of the methyl linoleate contained in the pharmaceutical composition of the present invention is not particularly limited, but may be in the range of 0.0001 to 50% by weight, more preferably 0.01 to 20% by weight, based on the total weight of the final composition.

The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount " of the present invention means a therapeutic or prophylactic treatment of a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention And the effective dose level refers to the level of the disease to be treated, the severity of the disease, the activity of the drug, the age, body weight, health, sex, sensitivity of the patient to the drug, Duration, duration of administration, factors involved in combination with or contemporaneously with the composition of the present invention, and other factors well known in the medical arts. The pharmaceutical composition of the present invention may be administered alone or in combination with a known hyperlipemia therapeutic agent. It is important to take into account all of the above factors and administer an amount that will achieve the maximum effect in the least amount without side effects.

The dosage of the pharmaceutical composition of the present invention can be determined by those skilled in the art in consideration of the purpose of use, the degree of addiction to the disease, the age, body weight, sex, history, or kind of the substance used as the active ingredient. For example, the pharmaceutical composition of the present invention may be administered at about 0.1 ng to about 100 mg / kg, preferably 1 ng to about 10 mg / kg, per adult, and the frequency of administration of the composition of the present invention is particularly It is not limited, but it can be administered once a day or divided into several doses. The dose is not intended to limit the scope of the invention in any way.

In another aspect, the present invention provides a method for preventing or treating hyperlipidemia, comprising administering the pharmaceutical composition to a subject in a pharmaceutically effective amount except for a human suffering from or susceptible to hyperlipidemia.

The term "individual" of the present invention may include, without limitation, mammals such as rats, livestock and the like, which have the possibility of developing hyperlipemia, or aquaculture.

The administration route of the pharmaceutical composition for preventing or treating hyperlipidemia of the present invention can be administered through any ordinary route as long as it can reach the target tissue or organ. The pharmaceutical composition of the present invention is not particularly limited, but may be administered by intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration, intrapulmonary administration, rectal administration and the like ≪ / RTI > However, since the methylninolenic acid salt can be denatured by gastric acid when orally administered, the oral composition should be formulated so as to be coated with an active agent or protected from decomposition at the top. In addition, the composition may be administered by any device capable of transferring the active agent to the target cell.

Another aspect of the present invention provides a food composition for preventing or ameliorating hyperlipemia comprising methyl linolenic acid salt.

Since the methyl linolenic acid salt is a component separated from excess which has been used as herbal medicines in the past and proved its safety, the methyl linolenic acid salt separated from the above is prepared in the form of food which is common but can prevent or improve hyperlipidemia . At this time, the content of the methylninolenic acid salt contained in the food is not particularly limited, but may be in the range of 0.001 to 10% by weight, more preferably 0.1 to 1% by weight based on the total weight of the food composition. When the food is a beverage, it may be contained in a proportion of 1 to 10 g, preferably 2 to 7 g based on 100 ml. In addition, the composition may contain additional ingredients which are commonly used in food compositions and which can improve odor, taste, vision and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid and the like. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn) and copper (Cu) It may also include amino acids such as lysine, tryptophan, cysteine, valine, and the like. In addition, it is also possible to use antiseptics (such as potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate), disinfectants (such as bleaching powder and highly bleached white powder, sodium hypochlorite), antioxidants (butylhydroxyanilide (BHA), butylhydroxytoluene BHT), etc.), coloring agents (such as tar pigments), coloring agents (such as sodium nitrite and sodium acetic acid), bleaching agents (sodium sulfite), seasoning (such as MSG sodium glutamate), sweeteners (such as hypoglycemia, , Food additives such as flavorings (vanillin, lactones, etc.), swelling agents (alum, potassium hydrogen D-tartrate), emulsifiers, emulsifiers, thickeners, encapsulating agents, gum bases, foam inhibitors, ) Can be added. The additives are selected according to the type of food and used in an appropriate amount.

Meanwhile, the health functional food for preventing or ameliorating hyperlipidemia can be prepared using the food composition for preventing or improving hyperlipidemia, which comprises the methyl linolenic acid salt.

For example, the food composition can be used to produce processed foods that can prevent or ameliorate hyperlipidemia, such as confectionery, drinks, liquor, fermented foods, canned foods, processed milk products, ≪ RTI ID = 0.0 > and / or < / RTI > The sweets include biscuits, pies, cakes, breads, candies, jellies, gums, cereals (including dinner utensils such as cereal flakes). Drinks include drinking water, carbonated beverages, functional ionic beverages, juices (such as apples, pears, grapes, aloes, citrus fruits, peaches, carrots, tomato juices, etc.) and sikhye. The mainstream includes sake, whiskey, shochu, beer, liquor, and fruit wine. Fermented foods include soy sauce, miso, and kochujang. Canned products include canned goods (eg, tuna, mackerel, saury, canned fish, etc.), canned products (beef, pork, chicken, turkey canned food, etc.) and canned products (corn, peach and canned pineapple). Milk processed foods include cheese, butter, yogurt and the like. Meat-processed foods include pork cutlet, beef cutlet, chicken cutlet, sausage. Sweet and sour pork, nuggets, and nubani. And noodles such as sealed packaging raw noodles. In addition, the composition may be used in retort food, soup and the like.

The term "functional food " of the present invention refers to a food for special health use (FoSHU) The food may be prepared in various forms such as tablets, capsules, powders, granules, liquids, rings and the like in order to obtain a useful effect for improving the fatty liver.

Another aspect of the present invention provides a composition for feeding or preventing hyperlipidemia comprising methyl linolenic acid salt.

Since the methyl linolenic acid salt can prevent or ameliorate hyperlipemia in an animal, it can be produced in the form of an animal feed animal which can prevent or improve hyperlipemia such as livestock and can be fed to an animal.

The composition for feed addition of the present invention may further comprise an excipient and a diluent which can be used for the production of feed. The excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, stevia extract and natural material extract.

In addition, the composition for feed addition of the present invention is useful not only for the methylninolenic acid salt mentioned above, but also for the nucleotides, enzymes and trace components necessary for the complete supply of essential nutrients required for productivity or health promotion of livestock, May be further included. For example, as nucleotides, 5'-adenylic acid, xanthic acid, ribonucleic acid, and deoxyribonucleic acid can be used alone or in combination; Examples of the enzymes include arabinase, arabinofuranosidase, galactanase, pectinase, maltase, invertase, lipase, ) May be used alone or in combination; As trace constituents, amino acid, calcium, phosphoric acid, organic acid, etc. may be used alone or in combination; Examples of the microorganism include Leuconostoc sp. Strain, Weisella sp. Strain, Enterococcus sp. Strain, Streptomyces sp. Strain, Nocardia sp. Nocardia sp.) May be used alone or in combination.

Another aspect of the present invention provides a feed for livestock comprising the feed composition as described above, which exhibits an effect of preventing or improving hyperlipidemia.

As described above, the methyl linolenic acid salt provided in the present invention can prevent or ameliorate hyperlipidemia without any toxicity when fed to an animal. Therefore, the feed for livestock produced by mixing the methyl linolenic acid salt with a raw material can improve the health of livestock Effect can be shown.

The livestock that can feed the livestock feed provided by the present invention is not particularly limited as long as it exhibits an effect of preventing or ameliorating hyperlipidemia due to methyl linolenic acid. Examples of such livestock include chickens, ducks, geese, cows, Sheep, horses, dogs, pigs, and the like.

The term "raw material feed" of the present invention means a feed to which the feed composition is added.

In the present invention, the raw material feed is not particularly limited as long as the feed additive is added to prevent or ameliorate hyperlipidemia of livestock. Examples include rice, fermented soybean meal, soybean, Italian grass, Sudan grass, Rye, rice straw, corn, wheat bran, rice bran, sugar beet or the like alone or in combination as a main component, and these main components may be included in an appropriate range generally used for livestock feedstuffs.

The term "compounded feed " of the present invention refers to a feed made by mixing together nutrients suitable for the purpose of raising livestock. The compounded feed includes nutrients such as energy, protein, lipid, . When making compounded feeds, nutritionally, it is necessary to have a proper amount of solid matter (solid matter) to promote the appetite of livestock and promote the normal action of digestive organs, An adequate amount of protein should be added, the amount of calories needed to keep the livestock body temperature and production normal, and other minerals and vitamins such as calcium or phosphorus.

On the other hand, the content of the feed additive composition contained in the feed is not particularly limited, but may be, for example, 0.01 to 10% (w / w) based on the final weight of the feed, % (w / w), and as another example 1% (w / w).

In addition to the above-mentioned main ingredients, the feeds may contain plasma proteins, fish meal, whey, complex dairy products, soybean oil, amino acid premix, acidic premix, red ginseng, salt, and vitamin- Or may be further included.

In another aspect, the present invention provides a pharmaceutical composition for the prevention or treatment of hyperlipidemia, which comprises as an active ingredient, a fraction obtained by successively fractionating an excess ethanol extract with dichloromethane, n-hexane and methanol .

Since the methyl linolenic acid salt of the present invention is isolated and purified from the fraction obtained by sequentially fractionating the excess ethanol extract with dichloromethane, n-hexane and methanol, the fraction may also have an effect of preventing or treating hyperlipidemia .

The composition comprising the methyl linolenic acid salt provided in the present invention can be effectively utilized for preventing, treating or improving hyperlipidemia without side effects, and thus it can be widely used in the development of various forms of hyperlipidemia therapeutic agents.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic diagram showing the flow of a process of separating and purifying methylurilate from an excess extract. FIG.
2A is a photomicrograph showing the difference in the level of fat contained in adipocytes according to the treatment concentration of methyl linoleate.
FIG. 2B is a graph showing the results of comparing changes in fat content according to the treatment concentration of methyl linoleate in differentiated adipocytes. FIG.

Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

Example  1: Excess extract methyl Linolenic  Separation purification

Methyl linolenate was separated and purified from the excess extract (Fig. 1). BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic diagram showing the flow of a process of separating and purifying methylurilate from an excess extract. FIG.

First, 80% of ethanol was added to 9.5 kg of dry matter purchased from Kyungdong market and extracted twice at room temperature. The extract solution was filtered to obtain a liquid component. The liquid component was applied to a rotary vacuum concentrator (EYEKA, N-100, Japan) to remove ethanol, and 538.5 g of an excess crude extract was obtained as a residue. The excess crude extract was suspended in distilled water, dichloromethane of the same volume as the distilled water was added, and mixed and left to obtain a dichloromethane fraction and a first water-soluble fraction, respectively.

The solvent was removed from the dichloromethane fraction and 146 g of a dichloromethane fraction was obtained. Further, an equal volume of ethyl acetate was added to the first water-soluble fraction, followed by mixing and left to obtain an ethyl acetate fraction and a second water-soluble fraction, respectively.

The solvent was removed from the ethylacetate fraction obtained above to give 40 g of ethyl acetate fractions. Further, the same volume of butanol was added to the secondary water-soluble fraction, followed by mixing and left to obtain a butanol fraction and a tertiary water-soluble fraction, respectively. The solvent was removed from the butanol fraction obtained above to obtain 85 g of a butanol fraction.

On the other hand, the dichloromethane fraction obtained above was suspended in n-hexane to obtain a suspension. The same volume of 50% methanol was added to the suspension, followed by mixing and standing to obtain a 50% methanol fraction and a primary n-hexane fraction Respectively. The same volume of 70% methanol was added to the primary n-hexane fraction and then mixed and left to obtain a 70% methanol fraction and a second n-hexane fraction. The same volume of 90% methanol was added to the secondary n-hexane fraction, followed by mixing and standing to obtain a 90% methanol fraction and a tertiary n-hexane fraction. The solvent was removed from the 90% methanol fraction to obtain 23 g of a 90% methanol fraction, and the solvent was removed from the tertiary n-hexane fraction to obtain 65 g of n-hexane fraction.

The obtained 90% methanol fractions were applied to silica gel column chromatography, from which six primary small fractions (G47-17-1 to G47-17-6) were obtained by sequential elution. At this time, n-hexane and chloroform were used as a developing solvent in a mixed solvent (1: 0, 1: 1 v / v), a mixed solvent of chloroform and methanol (1: 0, 50: 1, 30: : 1, 2: 1, 1: 1 v / v).

G47-17-2 selected from the first small fraction was applied to reverse phase column (ODS) chromatography, from which 20 secondary small fractions (G47-20-1 to G47-20-20) were obtained. At this time, a mixture solvent of methanol and water (30% - 100%) was used as a developing solvent.

G47-20-18 selected from the second sub-fraction was applied to Silicagel medium pressure liquid chromatography, and 9 tertiary sub-fractions (G47-22-1 to G47-22-9 ). At this time, n-hexane and chloroform were used as developing solvents.

G47-22-4 selected from the third small fraction was applied to high performance liquid chromatography, from which methyl linoleate was obtained. At this time, methanol and water were used as development solvents.

Example  2: methyl Linolenic  Verification of inhibitory activity of adipocyte differentiation

3T3-L1 (ATCC CL-173) cells, which are mouse derived lipid precursor cells, were inoculated into DMEM medium containing 10% BCS and cultured at 37 ° C and 5% CO ₂ . Cultured 3T3-L1 cells were plated at 5 × 10 ⁴ cells per well of a 24-well plate, cultured to 100% saturation, and maintained for 2 days. The adipocytes were induced for 2 days with 10% FBS DMEM medium containing MDI (0.5 mM 3-isobutyl-1-methylxanthine, 1 μM dexamethasone and 1 μg / ml insulin) And cultured for 2 days with 10% FBS DMEM containing 1 ug / ml insulin. Subsequently, the cells were replaced with 10% FBS DMEM medium for 2 days every 4 days. During induction of adipocyte differentiation, methyl linolenate was treated with 25, 50, and 100 uM of each culture medium, and adipocyte differentiation was observed on the 8th day when the differentiation was completed. The degree of adipocyte differentiation was firstly confirmed by microscopy through Oil Red O staining (Fig. 2a), and the degree of adipocyte staining was measured at 510 nm absorbance using an ELISA reader (SPECTRAmax 340PC, Molecular Devices, USA) (Fig. 2B).

FIG. 2 (a) is a microscope photograph showing the difference in fat levels contained in adipocytes according to the treatment concentration of methyl linoleate, FIG. 2 (b) is a graph showing changes in fat content according to the treatment concentration of methyl linolenate in differentiated adipocytes FIG. As shown in FIGS. 2A and 2B, it was confirmed that the treatment of methylninolate at the time of differentiation into adipocytes reduced the fat content of adipocytes in a concentration-dependent manner.

Therefore, methyl linolenic acid salt has an effect of reducing the synthesis of fat, and it can be shown that the effect of reducing the fat synthesis can prevent or treat hyperlipidemia induced by excessive fat.

Claims (7)

A pharmaceutical composition for preventing or treating hyperlipemia, comprising methyl linolenic acid salt.
The method according to claim 1,
Wherein said hyperlipidemia is hypertriglyceridemia, hypercholesterolemia, artery hardening, or a combination thereof.
The method according to claim 1,
Lt; RTI ID = 0.0 > pharmaceutically < / RTI > acceptable carrier, excipient or diluent.
A method for preventing or treating hyperlipidemia, comprising administering the pharmaceutical composition of any one of claims 1 to 3 to a subject other than a human who has or is likely to develop hyperlipidemia.
A food composition for preventing or ameliorating hyperlipidemia comprising methyl linolenic acid salt.
A composition for the feed addition for preventing or improving hyperlipemia comprising methyl linolenic acid salt.
Wherein the fraction is obtained by sequentially fractionating an excess of the ethanol extract with dichloromethane, n-hexane and methanol as an active ingredient.

Images